ELTX (Elicio Therapeutics) Non Operating Income: $0.96 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELTX Elicio Therapeutics Inc ELTX
26 GF Score
Price $1.77
View Full Analysis

What is Elicio Therapeutics Non Operating Income?

Elicio Therapeutics ELTX -11.50% 26 Non Operating Income is $0.96 Mil as of Jun. 2026. GuruFocus rates ELTX with a GF Score™ of 26/100.

Non Operating Income is income or expense that comes from miscellaneous sources. Elicio Therapeutics's Non Operating Income for the three months ended in Jun. 2026 was $0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $0.96 Mil.

Elicio Therapeutics Non Operating Income Related Terms

Elicio Therapeutics Non Operating Income Historical Data

* Premium members only.

The historical data trend for Elicio Therapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicio Therapeutics Non Operating Income Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Elicio Therapeutics Quarterly Data
Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ELTX
26GF Score
Elicio Therapeutics Inc ELTX
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicio Therapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $0.96 Mil mean?
Elicio Therapeutics (ELTX) has a Non Operating Income of $0.96 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Elicio Therapeutics and its competitors.
Is Elicio Therapeutics' Non Operating Income too high?
Elicio Therapeutics' current Non Operating Income is $0.96 Mil. Overall, Elicio Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' Non Operating Income compare to LONA and RNXT?
Elicio Therapeutics' Non Operating Income of $0.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Elicio Therapeutics and its competitors. Elicio Therapeutics's current Non Operating Income is $0.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current Non Operating Income of $0.96 Mil. The current Non Operating Income is $0.96 Mil. Elicio Therapeutics' overall GF Score™ is 26/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current Non Operating Income is $0.96 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges 9HA:Germany
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
26GF Score

Get the complete analysis for ELTX

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.77
Price